ライフサイエンスコーパス: craniospinal irradiation

1 iospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation).

2 ous peripheral blood stem-cell rescue before craniospinal irradiation.

3 patients in ACNS0122 who received full-dose craniospinal irradiation.

4 consequence of chemotherapy or prophylactic craniospinal irradiation.

5 ed after 12 cycles of chemotherapy and local craniospinal irradiation.

6 Two of 3 received craniospinal irradiation (2,560/3,840 cGy) and (3,520/5,

7 Ninety-seven patients received craniospinal irradiation (23.4 Gy) followed by 55.8 Gy t

8 Craniospinal irradiation (24 Gy cranial/15 Gy spinal) wa

9 hosphamide (one to three cycles) followed by craniospinal irradiation (25.2 to 36 Gy) and a boost to

10 Craniospinal irradiation and chemotherapy were negativel

11 aged 3-16 years in patients (n=215) who had craniospinal irradiation and had been treated with a cur

12 ell-based therapies, immunotherapies, proton craniospinal irradiation and ongoing clinical trials off

13 Fourteen patients were treated with craniospinal irradiation, and 11 were treated with local

14 otocol, which included surgery, risk-adapted craniospinal irradiation (average risk, n = 186; high ri

15 NS relapse, treatment that delays definitive craniospinal irradiation by 6 months to allow for more i

16 To compare quality of survival after craniospinal irradiation (CSI) alone with survival after

17 l study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions

18 e these effects include deintensification of craniospinal irradiation (CSI) dose and volume.

19 Craniospinal irradiation (CSI) has long been a cornersto

20 (RT) in 57 (30%), local RT in 87 (45%), and craniospinal irradiation (CSI) in 49 (25%).

21 BIS4 trial aimed to avoid highly detrimental craniospinal irradiation (CSI) in children < 4 years of

22 Craniospinal irradiation (CSI) is a vital therapeutic ap

23 y and TrueBeam c-arm linear accelerators for craniospinal irradiation (CSI) of the neuro-axis.

24 ed the effect of treatment with reduced-dose craniospinal irradiation (CSI) plus a tumor bed boost ve

25 lloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive l

26 I trial of temozolomide stratified by prior craniospinal irradiation (CSI).

27 ment exposure, including historical therapy (craniospinal irradiation [CSI] >= 30 Gy, no chemotherapy

28 % male), age at diagnosis (mean, 8.6 years), craniospinal irradiation dose (median, 23.4 Gy), length

29 The median craniospinal irradiation dose was 23.4 GyRBE (IQR 23.4-2

30 olling for age at diagnosis and risk-adapted craniospinal irradiation dose, performance on the follow

31 patients consisted of surgical resection and craniospinal irradiation, followed by the same chemother

32 em-cell support after surgical resection and craniospinal irradiation is feasible in newly diagnosed

33 t of chemotherapy (yes vs no) and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no cranios

34 were treated with postsurgical risk-adapted craniospinal irradiation (n = 36 high risk [HR]; n = 90

35 Patients had craniospinal irradiation of 18-36 Gy radiobiological equ

36 y with or without second-look surgery before craniospinal irradiation on response rates and survival

37 We tested whether proton craniospinal irradiation (pCSI) encompassing the entire

38 d 54 Gy tumor-bed boost, compared with 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost used

39 ry 4 weeks, after completion of risk-adapted craniospinal irradiation to children with newly diagnose

40 treatment groups (no CRT, focal irradiation, craniospinal irradiation) using the chi(2) test.

41 In multivariable models, craniospinal irradiation was associated with a 1.5- to t

42 thirty survivors, 81.3% of whom had received craniospinal irradiation, were matched with 1,150 contro

43 matter (NWM) related to their treatment with craniospinal irradiation with or without chemotherapy, a